KR20040039437A - 카바페넴 화합물의 제조방법 - Google Patents
카바페넴 화합물의 제조방법 Download PDFInfo
- Publication number
- KR20040039437A KR20040039437A KR10-2004-7004533A KR20047004533A KR20040039437A KR 20040039437 A KR20040039437 A KR 20040039437A KR 20047004533 A KR20047004533 A KR 20047004533A KR 20040039437 A KR20040039437 A KR 20040039437A
- Authority
- KR
- South Korea
- Prior art keywords
- organic solvent
- carbapenem
- formula
- solid
- residual organic
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 55
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical class C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 title abstract description 35
- 239000003960 organic solvent Substances 0.000 claims abstract description 131
- 239000007787 solid Substances 0.000 claims abstract description 110
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 70
- 150000001875 compounds Chemical class 0.000 claims abstract description 53
- 239000011261 inert gas Substances 0.000 claims abstract description 30
- 238000005406 washing Methods 0.000 claims abstract description 22
- 125000003118 aryl group Chemical group 0.000 claims abstract description 15
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 9
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 78
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 78
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 69
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 63
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 49
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 48
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 43
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 43
- 239000000203 mixture Substances 0.000 claims description 36
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 33
- 229910052757 nitrogen Inorganic materials 0.000 claims description 26
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 21
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 20
- 238000004458 analytical method Methods 0.000 claims description 13
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 12
- -1 carbapenem compound Chemical class 0.000 claims description 11
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 10
- 238000001704 evaporation Methods 0.000 claims description 9
- 238000011946 reduction process Methods 0.000 claims description 6
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims description 4
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 4
- 229940011051 isopropyl acetate Drugs 0.000 claims description 4
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 4
- 239000013557 residual solvent Substances 0.000 claims description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- BSIMZHVOQZIAOY-SCSAIBSYSA-N 1-carbapenem-3-carboxylic acid Chemical compound OC(=O)C1=CC[C@@H]2CC(=O)N12 BSIMZHVOQZIAOY-SCSAIBSYSA-N 0.000 claims 34
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- 230000008020 evaporation Effects 0.000 claims 3
- 229910001873 dinitrogen Inorganic materials 0.000 claims 1
- 230000004907 flux Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- ZIHYVLFLVDRNED-UHFFFAOYSA-M sodium;2-methylhept-2-enoate Chemical compound [Na+].CCCCC=C(C)C([O-])=O ZIHYVLFLVDRNED-UHFFFAOYSA-M 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 abstract description 13
- 239000000126 substance Substances 0.000 abstract description 2
- 239000002904 solvent Substances 0.000 description 14
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000007790 solid phase Substances 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 4
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- ZFPGARUNNKGOBB-UHFFFAOYSA-N 1-Ethyl-2-pyrrolidinone Chemical compound CCN1CCCC1=O ZFPGARUNNKGOBB-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 238000005388 cross polarization Methods 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000000887 hydrating effect Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 229910001928 zirconium oxide Inorganic materials 0.000 description 2
- KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- BTMWJZPJQDYRFI-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1h-imidazo[4,5-c]pyridine Chemical compound C1N=CC=C2NCNC21 BTMWJZPJQDYRFI-UHFFFAOYSA-N 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- ASMQGLCHMVWBQR-UHFFFAOYSA-N Diphenyl phosphate Chemical compound C=1C=CC=CC=1OP(=O)(O)OC1=CC=CC=C1 ASMQGLCHMVWBQR-UHFFFAOYSA-N 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- LINDOXZENKYESA-UHFFFAOYSA-N TMG Natural products CNC(N)=NC LINDOXZENKYESA-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- FVUCWGGFZNLYLD-UHFFFAOYSA-M [Na+].C(C=CCCCC)C(=O)[O-] Chemical compound [Na+].C(C=CCCCC)C(=O)[O-] FVUCWGGFZNLYLD-UHFFFAOYSA-M 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- 229940041011 carbapenems Drugs 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000004475 heteroaralkyl group Chemical group 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000005633 phthalidyl group Chemical group 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- IYNZNZWNBXJNNC-UHFFFAOYSA-M sodium;1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate Chemical compound [Na+].[O-]C(=O)C1=CCC2CCN12 IYNZNZWNBXJNNC-UHFFFAOYSA-M 0.000 description 1
- RIXFEPKIRJODPT-UHFFFAOYSA-M sodium;6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate Chemical group [Na+].CC1C=C(C([O-])=O)N2C(=O)C(C(O)C)C21 RIXFEPKIRJODPT-UHFFFAOYSA-M 0.000 description 1
- 238000000279 solid-state nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
- C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
- C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
- C07D477/20—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
- C07D477/02—Preparation
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
각(°2쎄타) | D 간격(옹스트롬) | I/Imax(%) |
4.8 | 18.44 | 100 |
6.7 | 13.09 | 41 |
10.5 | 8.43 | 38 |
11.7 | 7.58 | 41 |
13.6 | 6.48 | 72 |
14.4 | 6.16 | 62 |
16.0 | 5.55 | 39 |
17.2 | 5.14 | 44 |
18.4 | 4.81 | 63 |
19.7 | 4.50 | 60 |
20.8 | 4.26 | 64 |
21.6 | 4.11 | 59 |
22.1 | 4.02 | 66 |
23.1 | 3.85 | 63 |
24.1 | 3.69 | 93 |
26.1 | 3.41 | 83 |
26.6 | 3.35 | 67 |
27.0 | 3.03 | 71 |
27.4 | 3.25 | 71 |
28.6 | 3.12 | 63 |
31.1 | 2.78 | 83 |
각(°2쎄타) | D 간격(옹스트롬) | I/Imax(%) |
4.8 | 18.48 | 59 |
6.8 | 13.02 | 24 |
7.8 | 11.27 | 21 |
10.4 | 8.50 | 49 |
11.8 | 7.51 | 34 |
13.6 | 6.51 | 55 |
14.4 | 6.13 | 51 |
15.2 | 5.82 | 27 |
17.3 | 5.13 | 32 |
18.5 | 4.78 | 58 |
19.0 | 4.67 | 64 |
19.7 | 4.50 | 62 |
20.9 | 4.24 | 58 |
21.9 | 4.06 | 100 |
23.1 | 3.85 | 39 |
24.1 | 3.69 | 46 |
24.5 | 3.63 | 65 |
26.1 | 3.41 | 51 |
26.5 | 3.36 | 37 |
26.9 | 3.31 | 34 |
27.7 | 3.22 | 75 |
28.7 | 3.11 | 32 |
30.0 | 2.98 | 33 |
31.1 | 2.87 | 47 |
32.3 | 2.77 | 49 |
각(°2쎄타) | D 간격(옹스트롬) | I/Imax(%) |
4.8 | 18.29 | 50 |
6.8 | 12.94 | 22 |
7.8 | 11.25 | 28 |
10.7 | 8.28 | 65 |
11.8 | 7.50 | 45 |
13.7 | 6.46 | 44 |
14.6 | 6.08 | 45 |
17.3 | 5.11 | 30 |
18.6 | 4.78 | 44 |
19.14 | 4.63 | 67 |
19.9 | 4.45 | 42 |
21.0 | 4.22 | 35 |
22.1 | 4.02 | 100 |
24.2 | 3.67 | 60 |
26.1 | 3.41 | 50 |
27.9 | 3.20 | 59 |
31.3 | 2.86 | 38 |
32.5 | 2.75 | 39 |
Claims (22)
- 함수 유기 용매로 유기 용매를 함유하는 결정질 카바페넴을 세정하여 잔류 유기 용매를 함유하는 세정된 카바페넴 고형을 제조하고; 세정한 카바페넴 고형속의 잔류 유기 용매를 진공 및/또는 불활성 기체를 사용하여 저온에서 증발시켜 약제학적으로 허용되는 수준의 잔류 유기 용매를 함유하는 결정질 카바페넴 고형을 제조(여기서 잔류 유기 용매를 조정하여, 결정질 카바페넴 고형의 함수량을 본 공정동안 약 13% 내지 약 25%로 유지한다)함을 포함하여, 약제학적으로 허용되는 수준으로 결정질 카바페넴속의 유기 용매의 수준을 감소시키는 방법.
- a) 함수 유기 용매로 유기 용매를 함유하는 카바페넴 고형을 세정하여 잔류 유기 용매를 함유하는 세정된 카바페넴 고형을 제조하는 단계 및b) 진공 및/또는 불활성 기체 스트림을 사용하여 저온에서 세정된 카바페넴 고형속의 잔류 유기 용매를 증발시켜 약제학적으로 허용되는 수준의 유기 용매를 함유하는 화학식 I의 카바페넴 고형을 제조하는 단계를 포함하여, 화학식 I의 카바페넴 고형 또는 이의 염 속의 유기 용매의 수준을 감소시키는 방법.화학식 I상기 화학식에서,R1및 R2는 동일하거나 상이하며, H 또는 임의 치환된 알킬, 아릴 및 헤테로아릴로부터 선택된다.
- 제2항에 있어서, 유기 용매가 메탄올, 에탄올, 1-프로판올, 2-프로판올, 메틸 아세테이트, 에틸 아세테이트, 이소프로필 아세테이트, 아세톤 및 메틸 에틸 케톤 또는 이의 혼합물로 이루어진 그룹으로부터 선택되고; 온도는 약 -15℃ 내지 약 20℃이고 공정 동안 카바페넴 고형의 함수량을 잔류 유기 용매를 조정하여, 약 13% 내지 약 25%로 유지시키는 방법.
- 제5항에 있어서, 공정 동안 카바페넴 고형의 함수량을 잔류 유기 용매를 조정하여, 약 16% 내지 약 22%로 유지시키는 방법.
- 제2항에 있어서, 고형의 함수량을 약 16 내지 약 22%로 유지시키기 위해 증발 단계를 약 0℃ 이하의 온도에서 진공하에 수행하거나; 약 0℃ 이하의 온도에서 불활성 기체 스트림을 사용하여 수행하거나; 진공하에 약 0℃ 이하의 온도에서 불활성 기체 스트림을 사용하여 수행하거나 또는 수화된 불활성 기체 스트림을 사용하여 수행하는 방법.
- 제2항에 있어서, 함수 유기 용매가, 약 1% 내지 약 5%(w/v) 함수 메틸 아세테이트, 아세토니트릴, 테트라하이드로푸란 및 아세톤으로 이루어진 그룹 또는 이의 혼합물로부터 선택되는 방법.
- 제6항에 있어서, 유기 용매가 약 2% 내지 약 4%(w/v) 함수 메틸 아세테이트인 방법.
- a) 약 1% 내지 약 5%(w/v) 함수 아세톤, 아세토니트릴, 테트라하이드로푸란, 메틸 아세테이트 또는 이의 혼합물로 이루어진 그룹으로부터 선택된 함수 유기 용매로 유기 용매를 함유하는 화학식 II의 카바페넴 고형을 세정하여 잔류 유기 용매를 함유하는 화학식 II의 세정된 카바페넴 고형을 제조하는 단계 및b) 진공 및/또는 불활성 기체를 사용하여 약 -15℃ 내지 약 20℃의 온도에서 화학식 II의 세정된 카바페넴 고형속의 잔류 유기 용매를 증발시켜 약제학적으로 허용되는 수준의 잔류 유기 용매를 함유하는 화학식 II의 카바페넴 고형을 제조하는 단계를 포함하는, 화학식 II의 카바페넴 고형내의 잔류 유기 용매의 수준을 약제학적으로 허용되는 수준으로 감소시키는 방법.화학식 II상기 화학식에서,X+는 Na+, K+및 Li+로부터 선택된다.
- 제8항에 있어서, 유기 용매가 메탄올, 에탄올, 1-프로판올 및 2-프로판올로 이루어진 그룹 또는 이의 혼합물로부터 선택되고; 함수 유기 용매는 약 2% 내지 약 4%(w/v) 물을 함유하는 메틸 아세테이트이고; 잔류 유기 용매 감소가 일어나는 동안 카바페넴 화합물의 함수량이 약 13% 내지 약 25%로 유지되는 방법.
- 제8항에 있어서, 증발 단계를 약 0℃ 이하의 온도에서 진공하에 수행하거나; 약 0℃ 이하의 온도에서 불활성 기체 스트림을 사용하여 수행하거나 또는 0℃ 이하의 온도에서 불활성 기체 스트림을 사용하여 진공 하에 수행하는 방법.
- 제10항에 있어서, 불활성 기체 스트림을 사용할 경우, 불활성 기체 스트림이 질소 기체이고 불활성 기체 스트림의 유속이 화학식 II의 화합물의 분석 그람당 약 0.3 내지 약 30 SLPH(표준 리터/시)인 방법.
- 제11항에 있어서, 잔류 용매 감소에 사용한 불활성 기체를 수화시켜 고형의 함수량을 잔류 유기 용매 감소 공정 동안 약 13% 내지 약 25%로 유지시키는 방법.
- a) 1 내지 5%(w/v) 함수 메틸 아세테이트로 유기 용매를 함유하는 화학식 IIa의 카바페넴 고형을 세정하여 잔류 유기 용매를 함유하는 화학식 IIa의 세정된 카바페넴 고형을 제조하는 단계 및b) 약 10℃ 이하의 온도에서 화합물의 분석 그람당 약 0.3 내지 약 30SLPH(표준 리터/시)의 질소 유속으로 수화된 질소 스트림을 사용하여 진공하에 화학식 IIa의 세정된 카바페넴 고형 속의 잔류 유기 용매를 증발시켜 약제학적으로 허용되는 수준의 잔류 유기 용매를 함유하는 화학식 IIa의 카바페넴 고형을 제조하는 단계를 포함하는, 화학식 IIa의 (4R, 5S, 6S, 8R, 2'S, 4'S)-3-[[2-[[3-카복시페닐)아미노]-카보닐]피롤리딘-4-일]티오]-4-메틸-6-(1-하이드록시에틸)-7-옥소-1-아자비사이클로[3.2.0]헵트-2-엔-2-카복실산 일나트륨 염의 카바페넴 고형속의 유기 용매의 수준을 감소시키는 방법.화학식 IIa
- 제13항에 있어서, 유기 용매가 메탄올, 에탄올, 1-프로판올 및 2-프로판올로 이루어진 그룹 또는 이의 혼합물로부터 선택되고; 메틸 아세테이트는 약 2% 내지 약4%(w/v) 물을 함유하고; 잔류 유기 용매 감소 동안 카바페넴 고형의 함수량이 약 13% 내지 약 25%로 유지되는 방법.
- 약 10℃ 이하의 온도에서 진공 및 화합물의 분석 그람당 약 0.3 내지 약 30 SLPH(표준 리터/시간)의 질소 유속으로 수화된 질소 스트림을 사용하여 잔류 유기 용매를 증발시켜 약제학적으로 허용되는 수준의 잔류 유기 용매를 함유하는 화학식 IIa의 카바페넴 고형을 제조함을 포함하는, C형의 화학식 IIa의 (4R, 5S, 6S, 8R, 2'S, 4'S)-3-[[2-[[3-카복시페닐)아미노]-카보닐]피롤리딘-4-일]티오]-4-메틸-6-(1-하이드록시에틸)-7-옥소-1-아자비사이클로[3.2.0]헵트-2-엔-2-카복실산 일나트륨 염의 카바페넴 고형속의 잔류 유기 용매의 수준을 감소시키는 방법.화학식 IIa
- 제15항에 있어서, 잔류 유기 용매가 메탄올, 에탄올, 1-프로판올, 2-프로판올, 메틸 아세테이트, 아세토니트릴, 테트라하이드로푸란 및 아세톤으로 이루어진 그룹 또는 이의 혼합물로부터 선택되고; 잔류 유기 용매 감소 동안 카바페넴 화합물의 함수량이 약 13% 내지 약 25%로 유지되는 방법.
- A형 또는 B형의 결정질 카바페넴을 함수 메틸 아세테이트, 함수 아세톤 또는 이의 혼합물로부터 선택된 유기 용매로 세정하고 화학식 IIa의 카바페넴 고형의 결정질 수화물 C형을 분리함을 포함하는, 화학식 IIa의 화합물의 신규한 결정질 수화물 C형을 제조하는 방법.화학식 IIa
- 제17항에 있어서, 결정질 화합물이 B형이고 카바페넴 고형, B형의 세정에 사용한 유기 용매가 2% 내지 약 4% 물을 함유하는 메틸 아세테이트인 방법.
- a) 유기 용매를 함유하는 카바페넴 고형을 무수 유기 용매로 세정하여 잔류 유기 용매를 함유하는 세정된 카바페넴 고형을 제조하는 단계 및b) 20℃ 이하의 온도에서 진공 및 수화된 불활성 기체 스트림을 사용하여 세정된 카바페넴 고형내의 잔류 유기 용매를 증발시켜 약제학적으로 허용되는 수준의 유기 용매를 함유하는 화학식 I의 카바페넴 고형을 제조(여기서, 불활성 기체 스트림은 고형의 함수량을 약 13 내지 약 25%의 수준에 이르게 하는 방식으로 수화된다)하는 단계를 포함하여, 화학식 I의 카바페넴 고형 및 이의 염속의 유기 용매의 수준을 감소시키는 방법.화학식 I상기 화학식에서,R1및 R2는 동일하거나 상이하며 H 또는 임의 치환된 알킬, 아릴 및 헤테로아릴로부터 선택된다.
- 제19항에 있어서, 유기 용매가 메탄올, 에탄올, 1-프로판올, 2-프로판올, 메틸 아세테이트, 에틸 아세테이트, 이소프로필 아세테이트, 아세톤, 및 메틸 에틸 케톤으로 이루어진 그룹 또는 이의 혼합물로부터 선택되고; 무수 유기 용매는 메탄올, 에탄올, 1-프로판올, 2-프로판올, 메틸 아세테이트 및 아세톤으로 이루어진 그룹 또는 이의 혼합물로부터 선택되며 수화된 불활성 기체는 질소인 방법.
- d-간격이 18.29, 12.94, 11.25, 8.28, 7.50, 6.46, 6.08, 5.11, 4.78, 4.63, 4.45, 4.22, 4.02, 3.67, 3.41, 3.20, 2.86 및 2.75 옹스트롬인 고체상 X-선 분말 회절 XRPD 패턴에 의해 특징지어지는, 화학식 IIa의 결정질 수화물인 C형의 (4R, 5S, 6S, 8R, 2'S, 4'S)-3-[[2-[[3-카복시페닐)아미노]-카보닐]피롤리딘-4-일]티오]-4-메틸-6-(1-하이드록시에틸)-7-옥소-1-아자비사이클로[3.2.0]헵트-2-엔-2-카복실산 일나트륨 염.화학식 IIa
- 제21항에 있어서, 도 5, C형에 따르는 x-선 분말 회절 패턴을 갖는 결정질 수화물.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32513001P | 2001-09-26 | 2001-09-26 | |
US60/325,130 | 2001-09-26 | ||
PCT/US2002/029879 WO2003027067A2 (en) | 2001-09-26 | 2002-09-20 | Process for making carbapenem compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040039437A true KR20040039437A (ko) | 2004-05-10 |
KR100628676B1 KR100628676B1 (ko) | 2006-09-27 |
Family
ID=23266556
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020047004533A KR100628676B1 (ko) | 2001-09-26 | 2002-09-20 | 카바페넴 화합물의 제조방법 |
Country Status (22)
Country | Link |
---|---|
US (1) | US7022841B2 (ko) |
EP (1) | EP1474426B8 (ko) |
JP (1) | JP4480396B2 (ko) |
KR (1) | KR100628676B1 (ko) |
CN (2) | CN100387599C (ko) |
AT (1) | ATE518864T1 (ko) |
AU (1) | AU2002341747B2 (ko) |
BR (1) | BRPI0212411B8 (ko) |
CA (1) | CA2461565C (ko) |
CY (1) | CY1112092T1 (ko) |
DK (1) | DK1474426T3 (ko) |
EA (1) | EA008168B1 (ko) |
ES (1) | ES2368997T3 (ko) |
HU (1) | HU230700B1 (ko) |
IL (1) | IL160413A0 (ko) |
MX (1) | MXPA04002797A (ko) |
NZ (1) | NZ531174A (ko) |
PL (1) | PL218808B1 (ko) |
PT (1) | PT1474426E (ko) |
RS (1) | RS52410B (ko) |
UA (1) | UA78524C2 (ko) |
WO (1) | WO2003027067A2 (ko) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002331885B2 (en) | 2001-09-26 | 2007-07-26 | Merck & Co., Inc. | Crystalline forms of ertapenem sodium |
JP2005509037A (ja) * | 2001-11-16 | 2005-04-07 | ランバクシー ラボラトリーズ リミテッド | 結晶イミペネム製造方法 |
WO2006059753A1 (en) * | 2004-11-30 | 2006-06-08 | Astellas Pharma Inc. | Novel oral pharmaceutical suspension of cefdinir crystal |
CN100457760C (zh) * | 2005-10-20 | 2009-02-04 | 上海交通大学 | 尔他培南钠盐的制备方法 |
WO2008062279A2 (en) * | 2006-11-20 | 2008-05-29 | Orchid Chemicals & Pharmaceuticals Limited | An improved process for the preparation of carbapenem antibiotic |
CN101367812B (zh) * | 2007-06-28 | 2011-04-27 | 山东轩竹医药科技有限公司 | 被巯基吡咯烷甲酰胺基环戊烯酸取代的培南衍生物 |
CN101372490B (zh) * | 2007-08-15 | 2011-02-09 | 山东轩竹医药科技有限公司 | 含有巯基氮杂环乙烯基氮杂环的培南衍生物 |
EP2303225B1 (en) | 2008-06-11 | 2013-11-20 | Ranbaxy Laboratories Limited | Compositions of Carbon Dioxide Adduct of Ertapenem and Polymorphic Forms of Ertapenem Monosodium Salt |
CN102558182B (zh) * | 2010-12-31 | 2015-02-11 | 石药集团中奇制药技术(石家庄)有限公司 | 一种厄他培南钠晶型及其制备方法 |
CN102363617B (zh) * | 2011-11-09 | 2013-09-18 | 上海希迈医药科技有限公司 | 一种厄他培南单钠盐结晶体及其制备方法 |
US20150038726A1 (en) * | 2012-04-04 | 2015-02-05 | Hospira, Inc. | Process for the preparation of carbapenem antibiotic |
WO2015087245A1 (en) | 2013-12-11 | 2015-06-18 | Unimark Remedies Ltd. | Process for preparation of ertapenem and salts thereof |
CN113416193B (zh) * | 2021-08-23 | 2021-12-17 | 凯莱英医药集团(天津)股份有限公司 | 厄他培南钠新晶型及其制备方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1283906C (en) | 1983-05-09 | 1991-05-07 | Makoto Sunagawa | .beta.-LACTAM COMPOUNDS AND PRODUCTION THEREOF |
IE60588B1 (en) | 1986-07-30 | 1994-07-27 | Sumitomo Pharma | Carbapenem compound in crystalline form, and its production and use |
JP3048196B2 (ja) * | 1991-06-20 | 2000-06-05 | 第一製薬株式会社 | カルバペネム誘導体 |
GB9202298D0 (en) | 1992-02-04 | 1992-03-18 | Ici Plc | Antibiotic compounds |
CZ290002B6 (cs) * | 1992-03-11 | 2002-05-15 | Sankyo Company Limited | Antimikrobiální karbapenemové deriváty, způsob výroby a farmaceutický prostředek |
ZA938438B (en) * | 1992-11-17 | 1994-06-20 | Sankyo Co | Crystalline carbapenem derivative |
WO1997041123A1 (fr) * | 1996-04-26 | 1997-11-06 | Sankyo Company, Limited | Derives de 1-methylcarbapeneme |
US6180783B1 (en) * | 1997-06-16 | 2001-01-30 | Merck & Co., Inc. | Stabilized carbapenem intermediates and improved process for carbapenem synthesis |
US5872250A (en) | 1997-07-30 | 1999-02-16 | Merck & Co., Inc. | Process for synthesizing carbapenem antibiotics |
ES2260900T3 (es) | 1998-03-02 | 2006-11-01 | MERCK & CO., INC. | Procedimiento para sintetizar antibioticos de carbapenem. |
TWI250160B (en) * | 1999-07-06 | 2006-03-01 | Sankyo Co | Crystalline 1-methylcarbapenem compound |
AR035728A1 (es) * | 2001-01-16 | 2004-07-07 | Merck & Co Inc | Proceso perfeccionado para la sintesis de carbapenem |
AU2002331885B2 (en) * | 2001-09-26 | 2007-07-26 | Merck & Co., Inc. | Crystalline forms of ertapenem sodium |
-
2002
- 2002-09-20 ES ES02775896T patent/ES2368997T3/es not_active Expired - Lifetime
- 2002-09-20 MX MXPA04002797A patent/MXPA04002797A/es active IP Right Grant
- 2002-09-20 HU HU0500329A patent/HU230700B1/hu unknown
- 2002-09-20 AT AT02775896T patent/ATE518864T1/de active
- 2002-09-20 JP JP2003530658A patent/JP4480396B2/ja not_active Expired - Lifetime
- 2002-09-20 WO PCT/US2002/029879 patent/WO2003027067A2/en active IP Right Grant
- 2002-09-20 US US10/485,134 patent/US7022841B2/en not_active Expired - Lifetime
- 2002-09-20 EA EA200400474A patent/EA008168B1/ru unknown
- 2002-09-20 IL IL16041302A patent/IL160413A0/xx unknown
- 2002-09-20 DK DK02775896.0T patent/DK1474426T3/da active
- 2002-09-20 AU AU2002341747A patent/AU2002341747B2/en not_active Expired
- 2002-09-20 CN CNB2006100043356A patent/CN100387599C/zh not_active Expired - Lifetime
- 2002-09-20 RS YU22404A patent/RS52410B/en unknown
- 2002-09-20 CA CA002461565A patent/CA2461565C/en not_active Expired - Lifetime
- 2002-09-20 EP EP02775896A patent/EP1474426B8/en not_active Expired - Lifetime
- 2002-09-20 PL PL371666A patent/PL218808B1/pl unknown
- 2002-09-20 CN CNB028184319A patent/CN100338064C/zh not_active Expired - Lifetime
- 2002-09-20 BR BRPI0212411A patent/BRPI0212411B8/pt not_active IP Right Cessation
- 2002-09-20 KR KR1020047004533A patent/KR100628676B1/ko active IP Right Grant
- 2002-09-20 UA UA20040403037A patent/UA78524C2/uk unknown
- 2002-09-20 NZ NZ531174A patent/NZ531174A/en not_active IP Right Cessation
- 2002-09-20 PT PT02775896T patent/PT1474426E/pt unknown
-
2011
- 2011-10-31 CY CY20111101043T patent/CY1112092T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7145002B2 (en) | Crystalline forms of carbapenem antibiotics and methods of preparation | |
AU2002331885A1 (en) | Crystalline forms of ertapenem sodium | |
US8729260B2 (en) | Process for the preparation of carbapenem using cabapenem intermediates and recovery of cabapenem | |
KR100628676B1 (ko) | 카바페넴 화합물의 제조방법 | |
NZ566460A (en) | An improved process for the preparation of beta-lactam antibiotic | |
US7071330B2 (en) | Process for carbapenem synthesis | |
AU2002341747A1 (en) | Process for making carbapenem compounds | |
AU2002234240A1 (en) | Improved process for carbapenem synthesis | |
US7078534B2 (en) | Process for the preparation of crystalline N-formimidoyl thienamycin monohydrate (imipenem monohydrate) | |
KR20020033734A (ko) | 염기성 항생물질ㆍ무기산염의 제조 방법 및 수산염중간체 | |
US20110288289A1 (en) | Preparation of Carbapenem Intermediate and Their Use | |
JP4500814B2 (ja) | イミペネム(imipenem)の新規な製造方法 | |
HRP20040264A2 (en) | Process for making carbapenem compounds | |
JP2003183281A (ja) | カルバペネム化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120830 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20130830 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20140828 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20160629 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20170629 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20180628 Year of fee payment: 13 |